ArticleCancers2020
An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy of therapeutic modalities for metastatic uveal melanoma: a systemic review and network meta-analysis.Frontiers in oncology · 2026Pooled it
- Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases.Cardiovascular and interventional radiology · 2026Article
- Intensive Surveillance and Aggressive Multimodal Treatment for Liver Metastases From Uveal Melanoma.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2025Article
- Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients.The oncologist · 2025Article
- Going Rogue: Mechanisms, Regulation, and Roles of Mutationally Activated GMolecular pharmacology · 2024Review
- Identifying biomarkers for treatment of uveal melanoma by T cell engager using a QSP model.NPJ systems biology and applications · 2024Article
- A centrosome-related gene signature for predicting the overall survival of uveal melanoma.Translational cancer research · 2024Article
- Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?Seminars in interventional radiology · 2024Review
- Identification of a novel immune-related gene signature for prognosis and the tumor microenvironment in patients with uveal melanoma combining single-cell and bulk sequencing data.Frontiers in immunology · 2023Article
- Article
- Article
- Article
- Uveal Melanoma Metastasis.Cancers · 2021Review
- Review
- Review
- Role of Natural Killer Cells in Uveal Melanoma.Cancers · 2020Review
- Update on uveal melanoma: Translational research from biology to clinical practice (Review).International journal of oncology · 2020Review
- Locoregional Therapies for the Treatment of Uveal Melanoma Hepatic Metastases.Seminars in interventional radiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is no FDA-approved treatment for metastatic uveal melanoma (UM) and overall outcomes are generally poor for those who develop liver metastasis. We performed a retrospective single-institution chart review on consecutive series of UM patients with liver metastasis who were treated at Thomas Jefferson University Hospital between 1971-1993 (Cohort 1,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.